Understanding EIDD-1931 Dosing for Feline Calicivirus: Why Lower Can Be Better

We've received inquiries about our CaliciX™ dosing recommendations, from those who've read recent studies suggesting higher doses (15-17 mg/kg BID) for feline calicivirus-associated conditions. This is an excellent question that deserves a detailed, evidence-based answer.

The Studies You're Reading

Recent publications, including protocols from compounding pharmacies like Bova, recommend EIDD-1931 (molnupiravir) at:

• 17 mg/kg BID for feline chronic gingivostomatitis (FCGS)

• 15 mg/kg BID for FIP treatment

These doses are based on extrapolation from FIP protocols and early clinical observations. They represent a reasonable starting point, but they may not be optimal for all FCV-associated conditions.

Why We Recommend Lower Initial Doses

Our dosing protocol (5-10 mg/kg BID) is based on three clinical considerations:

1. FCV ≠ FIP: Different Diseases Require Different Strategies

FIP is an acute, rapidly progressive, and typically fatal disease. Aggressive dosing is justified because:

• Treatment duration is finite (12-16 weeks)

• The alternative is death

• Risk-benefit heavily favors maximum antiviral effect

FCV infections (URI, stomatitis, chronic carriers) are:

• Chronic or recurring throughout the cat's lifetime

• Rarely immediately life-threatening

• Managed over years, not months

Cumulative exposure matters. A cat treated for FIP receives ~3-4 months of exposure. A cat with recurring FCV symptoms might receive multiple treatment courses over 10-15 years. Minimizing per-treatment exposure becomes strategically important.

2. Clinical Heterogeneity: Not All FCV Conditions Are Equal

The term "FCV infection" encompasses:

• Upper respiratory infections (URI): Often self-limiting, respond well to supportive care

• Oral ulcers: Acute, painful, but typically resolve in 7-14 days

• Chronic gingivostomatitis (FCGS): Severe, refractory, immune-mediated inflammation

• Limping syndrome: Transient arthralgia

• Chronic shedders: Asymptomatic or mild intermittent symptoms

Our clinical experience (spanning thousands of FCV treatment courses across Southeast Asia, North America and Europe) shows:

• Mild-moderate cases respond adequately to 5-7 mg/kg BID

• Severe/refractory FCGS may require 10-15 mg/kg BID or higher

• Starting lower and escalating based on response optimizes risk-benefit

The 17 mg/kg dose in published protocols is appropriate for severe, refractory FCGS cases. It's unnecessarily high for mild URI or oral ulcers.

3. Safety Profile: Managing Known Risks

EIDD-2801 (molnupiravir prodrug) has demonstrated:

In vitro cytotoxicity: Mutagenic mechanism requires careful therapeutic window management

Gastrointestinal effects: Diarrhea and decreased appetite reported at higher doses, particularly in:

• Smaller cats (<2.5 kg)

• Geriatric patients

• Cats with pre-existing GI sensitivity

Long-term effects unknown: Unlike FIP (short-term use), FCV treatment may span years. Conservative dosing with PRN escalation minimizes cumulative exposure risk.

Our Clinical Protocol

We use a "minimum effective dose" approach:

Starting Doses (CaliciX™ Standard):

• Cats <2.5 kg: ~6 mg/kg BID (15 mg capsule)

• Cats 2.5-5 kg: ~6 mg/kg BID (two 15 mg capsules)

Escalation Protocol:

If symptoms don't adequately improve within 7-14 days:

1. Increase to CaliciX™ Max (30 mg capsule)

2. Reassess viral load (if PCR available)

3. Consider up to 15-17 mg/kg BID for refractory FCGS

Treatment Duration:

• URI/acute oral ulcers: 14-21 days

• FCGS: 60-90 days initial course, with maintenance as needed

• Chronic shedders: Intermittent courses during flare-ups

When Higher Doses Are Appropriate

We don't dismiss high-dose protocols. They're appropriate for:

• Severe, refractory FCGS unresponsive to lower doses

• Cases where rapid viral suppression is critical (shelter outbreaks, pre-surgical stabilization)

• Patients who've failed standard treatments

Our CaliciX™ Max formulation supports these scenarios.

What the Evidence Actually Shows

Truth: There are NO large-scale, dose-ranging studies for EIDD-1931 in FCV.

The 17 mg/kg recommendation is based on:

• Extrapolation from FIP protocols

• Anecdotal clinical experience

• Theoretical antiviral pharmacology

Our 6-12 mg/kg starting dose is based on:

• Clinical outcomes across >1,000 treatment courses

• Minimizing adverse effects while maintaining efficacy

• Long-term safety considerations for chronic disease

Both approaches are empirical. Neither has Level 1 evidence backing.

The Bottom Line

For veterinarians: Start with evidence-based conservatism. Most FCV cases respond to 5-10 mg/kg BID. Escalate systematically if needed. Document outcomes.

For cat owners: Trust your veterinarian to calibrate dosing based on your cat's specific condition severity, response to treatment, and tolerance.

For researchers: We need dose-ranging studies. FCV is not FIP. Optimal dosing likely varies by disease manifestation, viral strain, and immune status.

Transparency Matters

We developed our dosing based on real-world clinical feedback. We're constantly refining protocols as more data emerges. If you're seeing different recommendations elsewhere, that's because the science is still evolving.

We welcome dialogue with veterinarians who have different clinical experiences. Share your outcomes—let's build the evidence base together.

Questions? Contact our veterinary support team at hello@molnufip.com